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Abstract
Background: Genetic factors are known to contribute to COPD susceptibility and these factors are not fully
understood. Conflicting results have been reported for many genetic studies of candidate genes based on their
role in the disease. Genome-wide association studies in combination with expression profiling have identified a
number of new candidates including IREB2. A meta-analysis has implicated transforming growth factor beta-1
(TGFbeta1) as a contributor to disease susceptibility.
Methods: We have examined previously reported associations in both genes in a collection of 1017 white COPD
patients and 912 non-diseased smoking controls. Genotype information was obtained for seven SNPs in the IREB2
gene, and for four SNPs in the TGFbeta1 gene. Allele and genotype frequencies were compared between COPD
cases and controls, and odds ratios were calculated. The analysis was adjusted for age, sex, smoking and centre,
including interactions of age, sex and smoking with centre.
Results: Our data replicate the association of IREB2 SNPs in association with COPD for SNP rs2568494, rs2656069
and rs12593229 with respective adjusted p-values of 0.0018, 0.0039 and 0.0053. No significant associations were
identified for TGFbeta1.
Conclusions: These studies have therefore confirmed that the IREB2 locus is a contributor to COPD susceptibility
and suggests a new pathway in COPD pathogenesis invoking iron homeostasis.
Background
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality, and is pre-
dicted to become the 4
th leading cause of death by the
year 2030 [1]. Whilst smoking is a significant environ-
mental cause of COPD, not all smokers will develop dis-
ease. It is well recognised that COPD has a genetic
component as well as environmental, and that this may
account for these differences in susceptibility.
Many candidate gene studies have been carried out
over the past few years, with varying degrees of reprodu-
cibility. Conflicting results may be due to population
differences, spurious results caused by small sample
sizes and the subsequent low power of the study to
detect true associations or to variation in the phenotype.
Meta-analysis can be used to pool results from genetic
studies and give an overall conclusion, and this
approach has been used to summarise the results for
several COPD candidates [2]. This study revealed signifi-
cant associations for three polymorphisms in transform-
ing growth factor beta 1 (TGFB1), although it was
acknowledged that this was a limited analysis based on a
small number of studies.
Other strategies for identifying the genetic basis of
complex human disease include integrative approaches
which combine gene expression data with association
studies, or unbiased genome-wide approaches. Both of
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A recent genome-wide association study highlighted a
region on chromosome 15q25 which shows strong asso-
ciation to COPD [3]. This region contains several genes,
including members of the nicotinic acetylcholine recep-
tors (CHRNA5, CHRNA3 and CHRNB4)a n dt h ei r o n
regulatory protein 2 (IREB2). Although this region has
also been linked to lung cancer and nicotine addiction
as well as COPD [4,5], the strong levels of linkage dise-
quilibrium make it difficult to refine the location of the
true association signal and the functional variants. How-
ever, the expression of IREB2 has also been shown to be
altered in lung tissue from COPD patients compared to
controls [6], adding to the evidence for IREB2 acting as
a COPD susceptibility gene.
T h ea i mo ft h ec u r r e n ts t u d yw a st oi n v e s t i g a t ep o l y -
morphisms in the TGFB1 and IREB2 genes in our exist-
ing large collection of COPD cases and controls.
Methods
Subjects
COPD cases and control subjects were recruited at six
European centres. Numbers from each centre were: Bar-
celona - 70 controls and 138 cases; Bristol - 152 con-
trols and 129 cases; Dublin - 195 controls and 196
cases; Edinburgh - 81 controls and 168 cases; Leiden -
216 controls and 188 cases and Pisa - 198 controls and
198 cases. Approval for the study was obtained from the
appropriate committees at each recruitment centre.
Informed consent was obtained from all subjects. Cri-
teria for patient recruitment were a firm clinical diagno-
sis of stable COPD; airflow limitation as indicated by
FEV1 ≤70% normal predicted values and FEV1/FVC
<70%; no significant reversibility on bronchodilation and
as m o k i n gh i s t o r yo f≥20 pack years. Patients were
excluded from the study if they had an established diag-
nosis of asthma, lung cancer, a history of atopy, known
AAT deficiency or a serum AAT level of less than 1.0
g/L. They were also excluded if they had had an acute
exacerbation in the 4 weeks preceding assessment for
the study. Disease severity was classified according to
GOLD as follows: GOLD Stage II (moderate disease):
FEV1/FVC ratio of <0.70 and FEV1 predicted ≥50% and
<80%; GOLD Stage III (severe disease): FEV1/FVC ratio
of <0.70 and FEV1 predicted ≥30% and <50%; and
GOLD Stage IV (very severe disease): FEV1/FVC ratio
of <0.70 and FEV1 predicted <30% [7].
Control subjects were recruited at each centre to
match COPD patients for age, gender and smoking his-
tory. Exclusion criteria were as described for cases and
also included a family history of COPD. Only individuals
with no evidence of airflow obstruction (FEV1 and FVC
≥80% and FEV1/FVC >70%) were included in the
control group. Only white Caucasians were recruited for
cases and controls. Complete matching between cases
and controls was not achieved, but this was taken into
account during the analysis.
Genotyping of Study Samples
Four SNPs were chosen for TGFB1,w h i c hw e r et h e
same as the ones included in the recent meta-analysis
[2]. These were rs2241712, rs1800469, rs1800470 (for-
merly known as rs1982073) and rs6957. Seven SNPs
were included for IREB2, as identified by a recent publi-
cation [6]. These were rs2568494, rs2656069, rs1964678,
rs12593229, rs10851906, rs965604 and rs13180. Geno-
typing was carried out commercially by K-Bioscience
(Hertfordshire, UK). As a quality control measure,
approximately 5% of samples were genotyped in dupli-
cate to check for concordance. In addition, a selection
of samples were also genotyped using restriction enzyme
digestion, allele-specific PCR or direct sequencing to
confirm the genotyping results from K-Bioscience.
Statistical Analysis of Genetic variation
Each of the SNPs in the IREB2 and TGF1 genes was
analyzed for Hardy-Weinberg equilibrium (HWE) using
SAS/Genetics PROC ALLELE software [8]. HWE analy-
sis was performed on all controls and by each centre.
The analysis of allele and genotype frequencies in cases
and controls was performed using the same program.
The p-values and odds ratios for genotype and allele fre-
quencies are obtained by using SAS/Genetics PROC
LOGISTIC software. Odds ratios for individual SNP
allele distributions are relative to the common allele and
for genotypes they are relative to the major homozygous
genotype. The adjusted p-values and odds ratios with
95% confidence intervals for genotype and allele fre-
quencies adjust for age, sex, smoking and centre, includ-
ing interactions of age, sex and smoking with centre.
This adjustment was done to eliminate residual con-
f o u n d i n gd u et oa g e ,s e x ,s m o k i n ga n dc e n t r eu s i n g
logistic regression because matching was not completely
achieved on recruitment. Further, to assess the sensitiv-
ity of the analysis, we examined the adjusted odds ratios,
for individual SNP allele distributions relative to the
common allele, for each centre separately adjusting for
age, sex and smoking. Pairwise linkage disequilibrium
coefficients were calculated in controls using Haploview
[9].
Because there are significant differences in allele and
genotype frequencies between cases and controls for the
IREB2 gene, using FAMHAP18 [10,11] we examined all
possible two SNP and three SNP haplotypes for SNPs 1,
2 and 4 to explore if the haplotypes present significantly
stronger associations than single SNPs. We tested the
association of major and minor alleles with disease
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IV with Controls for TGF1 gene (SNPs 2, 3 and 4) and
for IREB2 gene (SNPs 1, 2 and 4). The chi-square test
of association of Major and Minor Alleles with severity
was done using SAS PROC FREQ software. An apparent
trend in the IREB2 gene for SNP allele frequency with
increasing severity was tested using SAS PROG GLM
software with CONTRAST statement. Using PROC
GLM in SAS, the quantitative trait associations between
SNPs and the phenotype FEV1 were tested by multivari-
ate regression, adjusting for age, sex, smoking and
centre.
Results
The study population characteristics for those subjects
with successful genotyping are summarised in Table 1.
Despite attempts to match cases and controls there
were significant differences observed and adjustments
were made by logistic regression to take this into
account in the statistical analysis. The characteristics of
recruited COPD patients across the GOLD severity cate-
gories are shown in Table 2. Out of 989 duplicate geno-
typing reactions there were 4 discordant results (0.4%).
The samples genotyped by alternative methods were
100% concordant, satisfying criteria for the assays to be
accepted for further analysis.
The values for linkage disequilibrium (LD) between
the SNPs are shown in Figure 1. This reveals very strong
levels of linkage disequilibrium between groups of SNPs
in both genes. Within TGFB1 there is strong LD
between SNPs 1 and 2 (rs2241712 and rs1800469; r
2 =
0.97), which is reflected in the very similar odds ratios
calculated as part of the published meta-analysis. Within
IREB2, it is clear that the seven SNPs studied fall into
three main groups. SNPs 2 and 5 are in linkage disequi-
librium (rs2656069 and rs10851906; r
2 = 0.99), as are
SNPs 3, 4, 6 and 7 (rs1964678, rs12593229, rs965604
and rs13180; all pairwise r
2 = 0.99). SNP 1 (rs2568494)
is not in linkage disequilibrium with any of the other
IREB2 SNPs (r
2 <0.34). For this reason, subsequent
tables show information for TGFB1 SNPs 2, 3 and 4,
and IREB2 S N P s1 ,2a n d4o n l y .T h e r ea r e5 1S N P si n
the region of IREB2 in HapMap, and using the 3
tagSNPs as presented here captures 64% of the variation
(33/51 variants). These calculations are harder to do for
TGFB1 as two of the SNPs we have used are not in
HapMap, so we cannot calculate the LD between these
SNPs and other variants in HapMap. There are only 8
SNPs in the TGFB1 region in HapMap, and rs1800469
captures information about one additional variant, ie 2
o u to f8S N P s( 2 5 % ) .I ti sl i k e l yt h a tw eh a v ec a p t u r e d
more variation than this, but are unable to quantify it
more precisely due to the lack of information about our
other two tagSNPs in HapMap.
Table 1 Characteristics of Controls and COPD subjects
Control COPD P-value
Male (%) 63.9 70.0 0.0049
Age (yr) 60.8 ± 8.9 65.9 ± 8.2 <0.0001
Smoking Pack Years 38.6 ± 17.3 48.8 ± 22.9 <0.0001
Predicted FEV1 (%) 95.3 ± 10.9 43.1 ± 15.1 <0.0001
FEV1/FVC (%) 77.8 ± 4.9 47.5 ± 12.1 <0.0001
N 900 1002
Values indicated are means ± SD. Pack Years missing for 6 COPD Cases.
Table 2 Characteristics of COPD patients according to
GOLD classification of disease severity
GOLD Status Moderate
II
Severe III Very Severe
IV
P-
value
Male (%) 74.9 67.1 67.6 0.0461
Age (yr) 66.0 ± 7.9 66.6 ± 8.4 64.3 ± 8.0 0.0021
Pack Years 49.5 ± 21.3 48.4 ±
22.4
48.6 ± 26.0 0.8043
Predicted FEV1
(%)
60.3 ± 5.9 39.9 ± 5.8 23.5 ± 4.3 <0.0001
FEV1/FVC (%) 57.1 ± 7.8 45.9 ± 9.9 36.2 ± 9.4 <0.0001
N 350 414 238
Values indicated are means ± SD. Pack years missing for 3, 2, 1 persons per
classification respectively.
Figure 1 Pairwise linkage disequilbrium between SNPs in the
TGFB1 gene (a) and IREB2 gene (b). Values shown are for r
2.
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Page 3 of 7HWE analysis showed that all SNPs are in HWE (p >
0.01 for all SNPs) (Table 3). The allele frequencies for
SNPs in cases and controls are shown in Table 4. None
of the TGFB1 SNPs showed significant associations with
COPD. This is in contrast to the significant associations
observed in the recent meta-analysis, which indicated
that the minor alleles of rs2241712, rs1800470 and
rs1800469 were associated with a reduced risk for
COPD, whilst rs6957 was associated with increased risk
[2]. Haplotype analysis also failed to demonstrate any
significant association with COPD (Additional file 1:
Table S1).
Each of the three IREB2 SNPs showed a significant
difference in allele frequency between cases and controls
(Table 4). A Sidak correction for multiple testing of 6
SNPs shows that a single p-value ≤ 0.0085 corresponds
to an overall p-value ≤ 0.05 [12]. Thus the significant
effects remained after adjustment for multiple compari-
sons. The genotype frequencies and associated odds
ratios for the IREB2 SNPs are shown in Table 5. Again
the genotype differences between cases and controls are
significant after the Sidak correction. This is in agree-
ment with previously published work [6]. Haplotype
analysis using IREB2 SNPs 1, 2 and 4 failed to yield any
significantly stronger associations than the single SNPs
alone (Additional file 1: Table S2).
We also analysed allele frequency differences between
each of the GOLD Stages II, III and IV and controls. No
significant differences or trends were observed for any of
the TGF1 SNPs. IREB2 SNPs 2 and 4 showed differ-
ences between severity groups and controls (not signifi-
cant after correction for multiple testing), but there
were no trends with increasing severity and the results
just reflect the overall case-control relationship (Table 6).
Whilst there appears to be a trend for an increase in
SNP 1 minor allele frequency with increasing severity,
this fails to reach statistical significance. Confining the
analysis to cases only we examined the relationship
between the allele distributions of the six SNPs and
severity of disease using the quantitative trait FEV1 as a
severity measure. We found no significant relationships
between FEV1 and the alleles.
Though there were significant differences between
centres for the allele distribution of some of the SNPs,
our results are unlikely to be due to population stratifi-
cation since cases and controls were matched within
centres. We also examined the genotype odds ratios for
all six SNPs in each centre (Additional file 1: Table S3).
The within-centre odds ratios for the three TGFB1
SNPs were all non-significant, showed no particular pat-
tern and fluctuated around the overall (all-centre) odds
ratios. The within-centre analysis for the IREB2 SNPs
showed that, though non-significant due to the smaller
sample size, the direction of the relationship was the
same in each centre as the all-centre results. Thus each
centre is showing the same IREB2 SNP relationships
with COPD.
Discussion
This study has replicated the associations seen for poly-
morphisms in IREB2 which have been previously
reported, but failed to reproduce the associations seen
in a recent meta-analysis for TGFB1. Recent studies
using cluster analysis suggest that SNP rs1800470 in
TGFB1 is associated with the emphysema-predominant
phenotype [13]. There is a plausible biological explana-
tion for this based on the critical role that TGFB1 plays
in reducing matrix metalloproteinase-12 activity, a key
mediator of emphysematous change. This is further sup-
ported by recent replicated studies showing that MMP-
12 variants are associated with a protective effect on
lung function and COPD [14,15]. The supposition is
that low levels of MMP-12 reduce the likelihood of
emphysematous change. Over-expression of TGFB1
would therefore predictably have the same protective
effect and reduced expression would be a predisposing
f a c t o r .T h i si sa l s os u p p o r t e db yw o r ki nam u r i n e
model of COPD, where activation of the TGF-Β signal-
ling pathway was observed alongside a partial rescue of
the emphysema phenotype [16]. We did not have phe-
notypic data to assess emphysema scores and so were
unable to test this proposition. It is also possible that
other genetic variants in the TGFB1 region which were
not investigated as part of the current study may be
involved in COPD susceptibility.
We have confirmed previous observations which sug-
gest that IREB2 variants may play a role in COPD. This
appears to be independent of an effect on lung function,
as we failed to detect any association between FEV1 and
any of the SNPs included in this study. This is in
Table 3 Characteristics of the SNPs
SNP Location in Gene Call
rate
(%)
HWE p
value in
controls
TGFB1 1 rs2241712 5’ region 94.4 0.470
2 rs1800469 5’ region 96.9 0.731
3 rs1800470 Exon 1 (Pro10Leu) 96.5 0.782
4 rs6957 3’ region 95.5 0.593
IREB2 1 rs2568494 Intronic 96.6 0.450
2 rs2656069 Intronic 96.7 0.470
3 rs1964678 Intronic 96.2 0.778
4 rs12593229 Intronic 97.0 0.802
5 rs10851906 Intronic 94.1 0.460
6 rs965604 Intronic 96.0 0.923
7 rs13180 Exon 21 (Ala872Ala) 94.9 0.935
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which looked for variants associated with lung function,
which also fails to find evidence for a role of IREB2
[17]. The IREB2 gene is located within the region identi-
fied by the COPD GWAS, and the high levels of linkage
disequilibrium in this area make it difficult to identify
the specific functional variant or gene which is underly-
ing this association. Only SNP 1 (rs2568494) is in rela-
tively high levels of linkage disequilibrium with SNPs
identified by the genome-wide study of COPD (HapMap
CEU data: r
2 = 0.790 with rs8034191 and r
2 = 0.692
with rs1051730), although the other IREB2 SNPs are
also in LD with variants in other genes in the region,
including CHRNA5. Identification of the genes and var-
iants contributing to the association with COPD will
require targeted resequencing of the region and further
functional work. In support of IREB2 involvement, a
previous publication has shown increased levels of
IREB2 mRNA in COPD patients versus controls [6].
This is an intriguing observation as this gene codes for
an iron binding protein. Iron homeostasis and free iron
concentration are likely to be important mediators of
oxidative stress and iron could therefore contribute to
local damage by this mechanism. IREB2 protein is
expressed in the lungs and cigarette smoking has been
associated with higher levels of iron in the lung [18].
IREB2 knock-out mouse models have a predisposition
to developing neurodegenerative disease due to aberrant
cellular iron homeostasis [19], though the lungs of these
animals were not examined in any detail. A potential
mechanism for distorted ion homeostasis relates to
membrane serine proteases (matriptases) which regulate
a number of biological effects. Genome-wide association
studies have shown that mutations in matriptase result
in refractory iron deficiency anaemia and the proteolytic
activity of matriptase is critical in regulating iron in this
form of anaemia as loss of function mutations result in
the disease [20]. The catalytic domain of matriptase is
Table 5 IREB2 Genotype frequencies and odds ratios in Controls and Cases
SNP
No
Locus Genotypes Controls COPD all
Cases
P-value Odds Ratio
+
Unadjusted Adjusted* Unadjusted Adjusted **
(95% C.I.)
1 rs2568494 GG 42.2 35.0 0.0004 0.0018 1 1
GA 46.4 48.4 1.26 1.24 (1.00, 1.55)
AA 11.4 16.6 1.77 1.77 (1.29, 2.44)
2 rs2656069 AA 63.1 69.3 0.0006 0.0039 1 1
AG 32.2 28.7 0.81 0.85 (0.68, 1.06)
GG 4.8 2.0 0.37 0.37 (0.20, 0.69)
4 rs12593229 GG 36.9 45.6 0.0001 0.0053 1 1
GT 48.0 43.9 0.74 0.79 (0.63, 0.98)
TT 15.1 10.5 0.56 0.61 (0.44, 0.84)
*p-values adjusted by logistic regression for age, sex, smoking and centre.
+Odds ratios are relative to the major homozygous Genotype.
**Adjusted by logistic regression for age, sex, smoking and centre.
Table 4 TGFΒ1 and IREB2 Allele frequencies and odds ratios in Controls and Cases
Gene SNP
No.
Locus Major/
Minor
Alleles
Minor
Allele Frequencies
Unadjusted
P-value
Adjusted
P-value*
Adjusted
Odds Ratio**
(95% C. I.)
Controls COPD
(all
cases)
TGFB1 2 rs1800469 C/T 0.32 0.32 0.8852 0.8314 1.02 (0.87, 1.18)
3 rs1800470 T/C 0.40 0.40 0.9118 0.8901 0.99 (0.86, 1.15)
4 rs6957 A/G 0.18 0.17 0.2736 0.2590 0.90 (0.74, 1.08)
IREB2 1 rs2568494 G/A 0.35 0.41 <0.0001 0.0005 1.30 (1.12, 1.50)
2 rs2656069 A/G 0.21 0.16 0.0004 0.0045 0.77 (0.64, 0.92)
4 rs12593229 G/T 0.39 0.32 <0.0001 0.0013 0.79 (0.68, 0.91)
*p-values adjusted by logistic regression for age, sex, smoking and centre.
**Adjusted odds ratios are relative to the major Allele, adjusted by logistic regression for age, sex, smoking and centre.
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conceivable that two major pathways associated with
progressive lung damage, namely proteolysis and oxida-
tive stress, are linked through iron homeostasis. This
could also explain the tendency for greater oxidative
stress in alpha1-antitrypsin deficiency as more active
matriptase may result in excessive free iron.
Conclusions
In summary, this study failed to replicate previous
reports of associations between SNPs in TGFB1 and
susceptibility to COPD, despite being adequately pow-
ered. This may be due to the possibility that the associa-
tion is actually with specific emphysema phenotypes
rather than overall susceptibility to disease, which could
not be assessed in this patient group. The replication of
the association between variants of IREB2 and COPD
provides further evidence to support the role of this
g e n o m i cr e g i o ni nC O P Dp a t h o g e n e s i s ,a n dt h er o l eo f
iron regulation deserves further investigation.
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